Surrogate endpoints: wishful thinking or reality?

被引：10

作者：

Burzykowski, Tomasz ^{[1
]}

机构：

[1] Hasselt Univ, Ctr Stat, B-3590 Diepenbeek, Belgium

来源：

STATISTICAL METHODS IN MEDICAL RESEARCH | 2008年 / 17卷 / 05期

关键词：

D O I：

10.1177/0962280207081866

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

页码：463 / 466

页数：4

共 14 条

[1] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[2]

BAKER SG, 2000, BIOSTATSTICS, V7, P58

[3] A perfect correlate does not a surrogate make [J].

Stuart G Baker ;

Barnett S Kramer .

BMC Medical Research Methodology, 3 (1) :1-5

[4]

BURZYKOWSKI T, 2005, EVALUTATION SURROGAT

[5] Criteria for the validation of surrogate endpoints in randomized experiments [J].

Buyse, M ;

Molenberghs, G .

BIOMETRICS, 1998, 54 (03) :1014-1029

[6]

Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49

[7] Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer:: a review of phase II/III trials [J].

Cunningham, D ;

Zalcberg, J ;

Maroun, J ;

James, R ;

Clarke, S ;

Maughan, TS ;

Vincent, M ;

Schulz, J ;

Barón, MG ;

Facchini, T .

EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) :478-486

[8]

Daniels M. J., 1997, STAT MED, V16, P1515

[9] STATISTICAL VALIDATION OF INTERMEDIATE END-POINTS FOR CHRONIC DISEASES [J].

FREEDMAN, LS ;

GRAUBARD, BI ;

SCHATZKIN, A .

STATISTICS IN MEDICINE, 1992, 11 (02) :167-178

[10]

Gail M H, 2000, Biostatistics, V1, P231, DOI 10.1093/biostatistics/1.3.231

← 1 2 →